Loading…
Loading…
[url="]Genmab A/S[/url] (Nasdaq: GMAB) today announced new data from two studies evaluating epcoritamab, a T-cell engaging antibody administered subcutaneously
New TALVEYÂ (talquetamab-tgvs) plus DARZALEX FASPROÂ (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combi
[url="]BeOne Medicines Ltd.[/url] (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 datas
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Li
Militia Long/Short Equity ETF offers retail investors access to a diversified, actively managed global long/short equity strategy, typically reserved for hedge funds. ORR's early performance is strong, with a 31.63% return since inception and a low portfolio beta of 0.43, despite high gross exposure. The fund employs a sophisticated portfolio construction, balancing global long positions with index and structural shorts for factor diversification.
[url="]Pfizer Inc. [/url](NYSE: PFE) today announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 B
RYBREVANT FASPRO⢠(amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where
[url="]Immunome, Inc.[/url] (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today a
SEC filings for ORR aren't indexed yet — common for recently launched funds. Browse the issuer's filings on SEC EDGAR directly.